Literature DB >> 9013391

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

M Gerlach1, P Riederer.   

Abstract

Animal models are an important aid in experimental medical science because they enable one to study the pathogenetic mechanisms and the therapeutic principles of treating the functional disturbances (symptoms) of human diseases. Once the causative mechanism is understood, animal models are also helpful in the development of therapeutic approaches exploiting this understanding. On the basis of experimental and clinical findings. Parkinson's disease (PD) became the first neurological disease to be treated palliatively by neurotransmitter replacement therapy. The pathological hallmark of PD is a specific degeneration of nigral and other pigmented brainstem nuclei, with a characteristic inclusion, the Lewy body, in remaining nerve cells. There is now a lot of evidence that degeneration of the dopaminergic nigral neurones and the resulting striatal dopamine-deficiency syndrome are responsible for its classic motor symptoms akinesia and bradykinesia. PD is one of many human diseases which do not appear to have spontaneously arisen in animals. The characteristic features of the disease can however be more or less faithfully imitated in animals through the administration of various neurotoxic agents and drugs disturbing the dopaminergic neurotransmission. The cause of chronic nigral cell death in PD and the underlying mechanisms remain elusive. The partial elucidation of the processes underlie the selective action of neurotoxic substances such as 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), has however revealed possible molecular mechanisms that give rise to neuronal death. Accordingly, hypotheses concerning the mechanisms of these neurotoxines have been related to the pathogenesis of nigral cell death in PD. The present contribution starts out by describing some of the clinical, pathological and neurochemical phenomena of PD. The currently most important animal models (e.g. the reserpine model, neuroleptic-induced catalepsy, tremor models, experimentally-induced degeneration of nigrostriatal dopaminergic neurons with 6-OHDA, methamphetamine, MPTP, MPP+, tetrahydroisoquinolines, beta-carbolines, and iron) critically reviewed next, and are compared with the characteristic features of the disease in man.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013391     DOI: 10.1007/BF01291788

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  228 in total

1.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

2.  MRI, brain iron and experimental Parkinson's disease.

Authors:  S Hall; J N Rutledge; T Schallert
Journal:  J Neurol Sci       Date:  1992-12       Impact factor: 3.181

Review 3.  Behavioural pharmacology of glutamate in the basal ganglia.

Authors:  W J Schmidt; M Bubser; W Hauber
Journal:  J Neural Transm Suppl       Date:  1992

Review 4.  Apoptosis and necrosis. Basic types and mechanisms of cell death.

Authors:  L M Buja; M L Eigenbrodt; E H Eigenbrodt
Journal:  Arch Pathol Lab Med       Date:  1993-12       Impact factor: 5.534

5.  The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

Authors:  D Ben-Shachar; G Eshel; J P Finberg; M B Youdim
Journal:  J Neurochem       Date:  1991-04       Impact factor: 5.372

6.  Free radical-generated neurotoxicity of 6-hydroxydopamine.

Authors:  R Kumar; A K Agarwal; P K Seth
Journal:  J Neurochem       Date:  1995-04       Impact factor: 5.372

7.  Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.

Authors:  M F Jarvis; G C Wagner
Journal:  Life Sci       Date:  1985-01-21       Impact factor: 5.037

8.  Enzymatic oxidation of the dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, into 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion.

Authors:  M Naoi; W Maruyama; J H Zhang; T Takahashi; Y Deng; P Dostert
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

Review 9.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

10.  Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure.

Authors:  F E Bloom; S Algeri; A Groppetti; A Revuelta; E Costa
Journal:  Science       Date:  1969-12-05       Impact factor: 47.728

View more
  92 in total

1.  Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting.

Authors:  D D Song; S N Haber
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

Review 2.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

3.  Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Authors:  Manfred Gerlach; Jürgen Beck; Peter Riederer; Maarten van den Buuse
Journal:  J Neural Transm (Vienna)       Date:  2011-01-28       Impact factor: 3.575

4.  Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.

Authors:  A Fredriksson; N Schröder; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

5.  Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons.

Authors:  Myung S Yoo; Hibiki Kawamata; Dae J Kim; Hong S Chun; Jin H Son
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 6.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

7.  Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.

Authors:  Hayato Kuroiwa; Hironori Yokoyama; Hiroki Kimoto; Hiroyuki Kato; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-04-30       Impact factor: 3.584

Review 8.  A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.

Authors:  Annalisa Pinna; Micaela Morelli
Journal:  Neurotox Res       Date:  2013-12-10       Impact factor: 3.911

9.  PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.

Authors:  Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

10.  Whole-Transcriptome Analysis of Mouse Models with MPTP-Induced Early Stages of Parkinson's Disease Reveals Stage-Specific Response of Transcriptome and a Possible Role of Myelin-Linked Genes in Neurodegeneration.

Authors:  A Kh Alieva; V S Zyrin; M M Rudenok; A A Kolacheva; M V Shulskaya; M V Ugryumov; P A Slominsky; M I Shadrina
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.